Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PBH Prestige Consumer Healthcare	$80.56 -0.7%	$84.12	$64.94 ▼ $90.04	$3.98B	0.45	300,294 shs	76,355 shs
RNA Avidity Biosciences	$29.97 +0.5%	$30.72	$21.51 ▼ $56.00	$3.61B	0.95	1.44 million shs	190,937 shs
RTRX Travere Therapeutics	$15.13 +1.2%	$26.56	$8.98 ▼ $24.96	$772.42M	0.67	412,277 shs	776,196 shs
RYTM Rhythm Pharmaceuticals	$61.18 -0.4%	$62.43	$39.46 ▼ $69.89	$3.89B	2.3	549,838 shs	138,126 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PBH Prestige Consumer Healthcare	-0.87%	-2.79%	-5.38%	-4.50%	+17.83%
RNA Avidity Biosciences	-0.23%	+1.74%	-1.71%	-5.60%	-25.26%
RTRX Travere Therapeutics	-1.94%	+3.71%	-5.65%	-26.63%	+81.15%
RYTM Rhythm Pharmaceuticals	-1.36%	-0.07%	+3.82%	+12.12%	+54.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PBH Prestige Consumer Healthcare	3.65 of 5 stars	2.3	2.0	0.0	3.5	2.1	1.7	1.9
RNA Avidity Biosciences	2.3338 of 5 stars	4.5	0.0	0.0	0.0	3.2	0.8	0.0
RTRX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	4.4073 of 5 stars	4.5	3.0	0.0	4.3	1.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PBH Prestige Consumer Healthcare	2.50	Moderate Buy	$93.33	15.86% Upside
RNA Avidity Biosciences	3.06	Buy	$65.59	118.82% Upside
RTRX Travere Therapeutics	0.00	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	3.00	Buy	$77.31	26.36% Upside

Current Analyst Ratings Breakdown

Latest RTRX, PBH, RYTM, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/11/2025	RNA Avidity Biosciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$65.00
6/10/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $75.00
6/10/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/10/2025	RNA Avidity Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/9/2025	RNA Avidity Biosciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$48.00 ➝ $54.00
6/9/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $75.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PBH Prestige Consumer Healthcare	$1.14B	3.50	$5.14 per share	15.68	$37.04 per share	2.17
RNA Avidity Biosciences	$10.90M	331.41	N/A	N/A	$11.94 per share	2.51
RTRX Travere Therapeutics	$175.34M	4.41	N/A	N/A	$5.15 per share	2.94
RYTM Rhythm Pharmaceuticals	$130.13M	29.91	N/A	N/A	$0.35 per share	174.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PBH Prestige Consumer Healthcare	$214.60M	$4.29	18.78	16.92	2.45	18.86%	12.87%	6.78%	8/6/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)
RTRX Travere Therapeutics	-$146.43M	-$3.46	N/A	N/A	N/A	-49.13%	-36.38%	-14.90%	N/A
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest RTRX, PBH, RYTM, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	PBH Prestige Consumer Healthcare	$1.30	$1.32	+$0.02	$1.00	$289.36 million	$296.52 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
RTRX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PBH Prestige Consumer Healthcare	0.55	4.20	2.82
RNA Avidity Biosciences	N/A	16.91	16.91
RTRX Travere Therapeutics	0.66	7.23	7.14
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PBH Prestige Consumer Healthcare	99.95%
RNA Avidity Biosciences	N/A
RTRX Travere Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
PBH Prestige Consumer Healthcare	1.60%
RNA Avidity Biosciences	3.83%
RTRX Travere Therapeutics	4.63%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PBH Prestige Consumer Healthcare	540	49.42 million	48.62 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable
RTRX Travere Therapeutics	221	51.05 million	N/A	Not Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

RTRX, PBH, RYTM, and RNA Headlines

Recent News About These Companies

Rhythm and Blues Show

June 27 at 2:56 AM | deltanews.tvD

Rhythm Pharmaceuticals Announces Late-Breaking Abstracts for ENDO 2025 Featuring Pivotal Phase 3 and Phase 2 Trial Results on Acquired Hypothalamic Obesity - Nasdaq

June 27 at 2:56 AM | nasdaq.com

Rhythm Pharmaceuticals' (RYTM) "Market Outperform" Rating Reiterated at JMP Securities

June 26 at 10:32 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25 at 2:27 PM | finanznachrichten.de

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25 at 8:00 AM | globenewswire.com

Avior Wealth Management LLC Invests $243,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 24 at 3:52 AM | marketbeat.com

22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A.

June 18, 2025 | marketbeat.com

SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 18, 2025 | marketbeat.com

GAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 18, 2025 | marketbeat.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 2,069 Shares of Stock

June 12, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Buy" from Analysts

June 12, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Buys 47,045 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wedge Capital Management L L P NC

June 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $478,459.55 in Stock

June 10, 2025 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year High - Should You Buy?

June 9, 2025 | marketbeat.com

The Rhythm Foundation seeks contract extension to continue programming at Miami Beach Bandshell

June 7, 2025 | msn.com

Heartbeats That Matter: The Silent Risks of Heart Rhythm Disorders

June 7, 2025 | deccanchronicle.comD

Millennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 7, 2025 | marketbeat.com

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

June 5, 2025 | msn.com

Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

June 5, 2025 | benzinga.com

Hennion & Walsh Asset Management Inc. Has $4.75 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RTRX, PBH, RYTM, and RNA Company Descriptions

Prestige Consumer Healthcare NYSE:PBH

$80.56 -0.59 (-0.73%)

As of 12:02 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Avidity Biosciences NASDAQ:RNA

$29.97 +0.14 (+0.48%)

As of 12:03 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Travere Therapeutics NASDAQ:RTRX

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Rhythm Pharmaceuticals NASDAQ:RYTM

$61.18 -0.27 (-0.44%)

As of 12:03 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time